Susan Rosenthal

Come meet me at the upcoming GLP-1-Based Therapeutics Summit, where I'll be sharing insights on real-world GLP-1 prescribing trends gleaned from Truveta Data.  #GLP1Summit #GLP1 #PrescriptionTrends #PrescribingTrends 

2

Tufts Center for the Study of Drug Development has partnered with Digital Medicine Society (DiMe) on the DATAcc by DiMe’s new project, “Building the Business Case for Digital Endpoints." This project will increase investment in digital measurement development and deployment in clinical trials by developing a value framework, industry benchmarking tools, ROI forecasting models, and a modular template business case framework to support innovators across the field to invest in digital endpoints and advance their broad adoption and scale in clinical research. To learn more about this project, visit https://bit.ly/3VuPALY Tufts CSDD's Joseph DiMasi and Zachary Smith are continuing with an advisory role on the project and have collaborated with CSDD's Abigail Dirks, MS, Ken Getz, and other industry leaders at Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda and MindMed on research "Assessing the Net Financial Benefits of Employing Digital Endpoints in Clinical Trials". To access the research article, visit https://bit.ly/3X3NeEW #digitalendpoints #clinicaltrials #research

23

1 Comment

Over the past two decades, the healthcare landscape has evolved significantly, marked by a surge in diverse data sources and an expansion of therapeutic choices. Stakeholders, including patients, healthcare providers, and payers, now seek and utilize complex information with a higher level of sophistication. This proliferation of data has led to increased expectations and demands for more intricate knowledge from all involved. Transforming medical leadership beyond traditional roles is essential in light of these changes. Diversification of expertise, development of business acumen, and a revised approach to measuring performance will be key for this transformation. #HealthcareLeadership #MedicalInnovation #DataTransformation #medicalaffairs

40

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

So humbled to partner with these amazing leaders in AI Healthcare and Biotech! Chief if you're in town for #NYCtechweek join us! #Healthcare #Biotech #AI #Leadership EVENT TITLE: 𝐇𝐋𝐖𝐅™ 𝐀𝐋𝐋𝐈𝐀𝐍𝐂𝐄 : IN-PERSON AI in Lifesciences- Women Leading Biomedical Innovation EVENT DETAILS: Join us for an invigorating panel discussion moderated by 𝐑𝐚𝐬𝐡𝐦𝐢 𝐑𝐚𝐨 https://lnkd.in/e9_hmpPe Founder of HLWF™ Alliance who will guide our exploration into the transformative role of AI in life sciences. This panel will feature five eminent women who are pioneering the integration of AI in healthcare: 𝐒𝐡𝐚𝐢𝐥𝐚𝐣𝐚 𝐃𝐢𝐱𝐢𝐭, CEO of Curio Digital Therapeutics, will delve into AI's role in enhancing drug development and optimizing health economics. https://lnkd.in/eCNK2Zjx 𝐂𝐡𝐫𝐲𝐬𝐚𝐧𝐭𝐡𝐢 𝐃𝐨𝐫𝐢, a leader in digital health, will discuss the impact of AI on improving healthcare delivery and patient outcomes through advanced data analytics. https://lnkd.in/ecwZZKQ7 𝐌𝐞𝐠 𝐇𝐞𝐢𝐦, SVP, Head of Global Medical Affairs Asklepios BioPharmaceutical, Inc. (AskBio) an expert in gene therapy and biotech, will highlight the revolutionary applications of AI in biopharmaceuticals and global health strategies. https://lnkd.in/eXhJv4DE 𝐃𝐨𝐫𝐢 𝐆𝐨𝐧𝐳𝐚𝐥𝐞𝐬 𝐀𝐜𝐞𝐯𝐞𝐝𝐨, head of ProcellaRX, will emphasize the significance of AI in ensuring regulatory compliance and quality in healthcare innovations. https://lnkd.in/eNcR_2S3 𝐁𝐞𝐭𝐡𝐚𝐧𝐲 𝐇𝐢𝐥𝐥𝐬 𝐆𝐨𝐫𝐢𝐬, a seasoned attorney, will explore how AI can navigate complex legal landscapes to bring cutting-edge solutions to market. https://lnkd.in/egyaewSc Recent trends in life sciences show a surge in AI-driven solutions that are reshaping everything from clinical trial designs to personalized medicine, offering predictive insights and enhanced decision-making capabilities. AI is also playing a crucial role in drug discovery, enabling faster and more efficient processes that could lead to breakthrough treatments for complex diseases. As we integrate these technologies, they promise to enhance patient care, streamline operations, and improve outcomes across the healthcare spectrum. Don’t miss this opportunity to gain invaluable insights from leading experts at the nexus of AI and life sciences, where innovation meets impactful healthcare solutions. Rashmi Rao | Chief Product Officer | Board Director | Women in Tech Hall of Fame | Top Voice | Forbes | WEF | Ex-APPL, SAMSUNG, QCOM

40

1 Comment

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend? https://lnkd.in/ezX4Dsmb Citeline Commercial #biopharma #clinicaltrials #RnD

9

BioPharma Sector highlights at your fingertips.

11

Tomorrow at MassBio's Align Summit, I'll be representing CytoReason on a panel with distinguished representatives from Genentech, BigHat Biosciences, BioNTech SE and Locust Walk. In the session "AI Partnerships: Integrating for Strategic Value" we'll bring up best practices for integrating AI/ML into pharma and biotech companies. We'll also discuss the the competitive advantages that these capabilities can unlock, and when to build, buy, or rent these capabilities. Thanks MassBio for organizing this important event, in partnership with Locust Walk and McKinsey & Company. For more info, see the link in comment below.

66

4 Comments

In the past two weeks, the biopharma industry has witnessed two multi-billion strategic partnerships fall apart as Sanofi cut half of its $6.2 billion deal with IGM Biosciences and Genentech terminated its T cell therapy partnership with Adaptimmune. This raises the question: what percentage of the BioBucks in a partnership deal actually get paid out, on average? Although companies rarely publish the unredacted deal terms of partnerships, nor do they publish which payments are actually made (unless material to a public company), nonetheless we can calculate the probability-adjusted expected value of the Sanofi-IGM and Genentech-Adaptimmune deals as shown below. I am using industry-typical probability of success by stage and am making rough guesses on how the milestones were distributed by stage. Such an expected value calculation can be thought of as answering the question: how much would the in-licensor expect to pay on average if they could conduct hundreds of experiments with these probabilities and deal terms. By the way, a more complete analysis would time-adjust the values with an NPV of cash flows but that is not shown here.   Sanofi-IGM deal was for 6 targets (3 cancer and 3 immunology/inflammation) with upfront of $150M and aggregate milestones of $940M per oncology target and $1,065M per immunology/inflammation target. Here is a rough cut at a probability-adjusted estimate of total payments to IGM Biosciences at the time the deal was signed, which at $909M is about 15% of the total BioBucks of $6.2B. #lifesciences, #businessdevelopment, #biotech

80

10 Comments

Takeda's CEO's annual letter hits on some key themes that many biopharma CEO's are converging on: value-based care, price transparency, breaking up the middlemen, and driving healthcare access and equity. "For several years I have been outlining Takeda’s thinking on health equity—including advocating for a transition to value-based health care that pays for outcomes and care quality, emphasizing the need to prepare for the next pandemic by ensuring global vaccine equity and explaining how the protection of intellectual property rights is essential to incentivize investment in R&D. One area where we would like to see greater progress this year is pharmacy benefit managers reform. We support efforts in Congress to delink rebates from list prices or wholesale acquisition cost. It is a complex system, but the bottom line is that the current system creates misaligned incentives that ultimately result in higher costs for the system and higher out-of-pocket costs for patients. One potential way to address these challenges is through greater transparency. Transparency at the point of purchase for patients would empower them to make decisions knowing exactly what their costs will be. This could lower costs for the entire system by building in greater pricing accountability along the chain so that no stakeholder can benefit from the inefficiencies that result in the prices that patients pay today." At COEUS, we are working with the world's leading biopharma companies to help transition them from a broken FFS model towards value-based care. We have built the world's leading platform that hosts the biggest CGT commercial launches, and rapidly moving into Oncology, Obesity/ Diabetes, and beyond. 1. Enabling Value-Based Healthcare: Our solution facilitates the transition to value-based healthcare by providing a powerful tool for creating and managing contracts that pay for outcomes and care quality. 2. Enhancing Transparency: By aggregating disparate healthcare data from various sources, our platform provides unprecedented transparency into the entire healthcare ecosystem. This empowers payers, providers, and patients to make informed decisions and helps stakeholders across the value-chain to tie price and value to therapeutic outcomes. 3. Driving Innovation: Our platform's ability to evaluate complex rules for value-based contracts, real-world evidence studies, and health equity measurements fosters innovation in the pharmaceutical industry. By providing a tool to measure the impact of new solutions, we help companies drive medical advancements while ensuring equitable access. 4. Improving Access and Affordability: Our solution helps identify areas where access and affordability can be improved without compromising innovation. By providing data-driven insights into the effectiveness of various interventions, we enable stakeholders to make informed decisions that benefit patients and the healthcare system as a whole. Visit https://coebra.ai/.

10

The countdown is on. Next week, I'm heading to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24). It's one of the most significant events in the oncology world, bringing together a global community of researchers, clinicians, advocates, and patients in the fight against cancer. For me, #ASCO24 is more than just a conference; it's a chance to: - Dive into the Latest Research: Thousands of abstracts will be presented, showcasing cutting-edge advancements across all aspects of cancer care. I'm eager to learn about new therapies, diagnostic approaches, and breakthroughs that can transform patients' lives. Discussing the evolving landscape of cancer treatment is crucial for staying updated on the latest developments and best practices in patient care. - Connect with Experts: Meeting and exchanging ideas with leading oncologists, scientists, and industry innovators is an invaluable experience. It fosters collaboration and fuels inspiration for advancing cancer care. - Share Our Recent Developments: Zephyr AI team will present a poster and share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data." Abstract # 5583 / Poster Bd # 454, presented by Emily Vucic et al., June 3rd, 9 am—12 pm: https://lnkd.in/g8wKqB8v In the meantime, what are you most interested in learning about from #ASCO24? Share your thoughts and questions. See you in Chicago!

28

1 Comment

Not all patients are concerned with the same things, even those dealing with life-threatening conditions. In this work, individuals who had survived Acute Leukemia were asked about their treatment preferences in the event of a relapse. Whilst all patients were concerned with the likelihood that they would respond to treatment, they differed in terms of their concern for other aspects of treatment. 💡This result emphasise that patients are still individuals, with their own distinct values and preferences, even when faced with a life-threatening condition. Healthcare providers and systems must account for these preferences when treating patients, even in the most urgent of circumstances. Thanks to the Acute Leukemia Advocates Network and especially Samantha Nier and Zack Pemberton-Whiteley for the opportunity to contribute to this research. #patientpreferences #AcuteLeukemia #healtheconomics

25

2 Comments

On the cross-country flight home from a wonderful and busy BIO International Convention, I spent some time reflecting on three years here at the National Pharmaceutical Council. I still remember flying to DC as the brand-new President and CEO of the organization in June 2021 – a trip that simultaneously feels like yesterday and a lifetime ago, given the changes in the industry, health policy, and research environment. The work of NPC has never been more relevant — or more important. We have a great team, and this team appreciates the challenges we face. Here are three reflections I’d offer for anyone interested in the future of innovation. • To meet the challenges of today and tomorrow, NPC has built new capabilities that allow us to build on our 70-year legacy as we conduct rigorous, policy-relevant research and communicate it with impact. I invite you to learn more about the value we provide to NPC members and the benefits member companies experience. https://lnkd.in/etCWVqTE • NPC’s research informs many of the important policy conversations going on right now. To stay up to date on our latest, I hope you subscribe to the NPC This Week Newsletter to get a weekly look-ahead at the policy, research, and industry conversations that matter to the future of biopharmaceutical innovation. https://lnkd.in/eBAj7B_B  • I’m proud of the team at NPC and what we’ve accomplished — while recognizing the challenges in front of us. If you’d like to see more of our recent research, analysis, and work, check out our 2023 Annual Report. https://lnkd.in/eB6u2nWd  I’ve loved every minute of the past three years and look forward to many more. These aren’t challenges we can solve alone, and it has never been more important for drugmakers, payers, and policymakers to understand the ecosystem and work together for the benefit of patients. If we haven’t spoken in a while, I’d love to hear from you, whether in the DMs, email, or phone.  #pharma #innovation #healthpolicy

114

14 Comments

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

A conversation about healthcare access is incomplete without a conversation about cost. This is an important article from Dr. Matthews. Healthcare costs are rising for treatment, consultations, and medications. This is making it difficult for patients to access healthcare, especially in areas that have limited healthcare options like rural communities. Achieving health equity requires assessing and addressing this issue. #HealthEquity #HealthcareAccess #healthcare

5

1 Comment

I just arrived in rainy Boston to join my friends Dr. D. Martin Alexander Gershon, MD, JD, MPH MPH and Rebecca Miksad, MD, MMS, MPH to participate on a panel to discuss a topic most of us in the healthcare world are focused on - and a big focus of ours at Click Therapeutics: Playing the Long Game: The Roadmap to Integrate AI into the Healthcare System Groundbreaking new technologies such as AI, Machine Learning, Deep Learning are intersecting with unprecedented advances in healthcare and life sciences research, dramatically reshaping drug discovery, drug development and personalized medicine. There's been $100 billion in investments by Big Tech in AI innovation and technology in healthcare and life sciences in the past few years. While tech giants are driving innovation and supporting emerging AI companies with billions of dollars of investment, hospital systems and emerging companies alike are finding it very difficult to navigate the complexities of AI integration into the healthcare system. This discussion will bring together thought leaders from hospitals, the pharmaceutical industry, academia and emerging unicorns to look at the roadmap to integrate AI technologies into the healthcare system https://lnkd.in/guggF3Jh

33

2 Comments

Eli Lilly and Company's shares were up 7% this morning on guidance that they are seriously ramping up their production capacity for their obesity and diabetes drugs, Mounjaro and Trulicity. They also increase their revenue forecast by $2B this year! We already know that diabetes drugs like Ozempic have become very mainstream and the drug companies are all making huge profits, but the question is, can the average consumer or aspiring founder benefit from this craze? The answer is yes. I've shared my POV time and time again that I think that drugs like Ozempic are going to have a massive impact on the global economy for the foreseeable future. I break down how I would approach capitalizing on the whitespace Ozempic is generating because this is truly a once in a life time opportunity. #startup #entrepreneur #ozempic #diabetes #weightloss

104

17 Comments

My fellow panelists at the Milken Institute Global Conference made excellent points, especially these:  we are in the early era of the "exponential curve" that will accelerate drug discovery with the help of AI, and it is going to take whole new models and innovative approaches to take maximum advantage of the potential. Great write up:

183

1 Comment

Personalized cancer vaccines represent the pinnacle of personalization in advanced therapies. These individualized treatments have the potential to be administered on a large scale. Manufacturers can gain valuable insights from the cell and gene therapy (C&GT) sector, which will be crucial in leveraging and engaging the ecosystem differently to turn this potential into reality. #CGT #Personalizedmedicine #Vaccines #Advancedtherapies #cellandgene. https://lnkd.in/ec_wP72G

6